KALV
Price
$12.00
Change
+$0.26 (+2.21%)
Updated
Apr 17 closing price
Capitalization
596.59M
75 days until earnings call
XOMAO
Price
$25.35
Change
+$0.18 (+0.72%)
Updated
Apr 17 closing price
Capitalization
N/A
Ad is loading...

KALV vs XOMAO

Header iconKALV vs XOMAO Comparison
Open Charts KALV vs XOMAOBanner chart's image
KalVista Pharmaceuticals
Price$12.00
Change+$0.26 (+2.21%)
Volume$495.51K
Capitalization596.59M
XOMA
Price$25.35
Change+$0.18 (+0.72%)
Volume$1.06K
CapitalizationN/A
KALV vs XOMAO Comparison Chart
Loading...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KALV vs. XOMAO commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KALV is a Hold and XOMAO is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (KALV: $12.00 vs. XOMAO: $25.35)
Brand notoriety: KALV and XOMAO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KALV: 81% vs. XOMAO: 33%
Market capitalization -- KALV: $596.59M vs. XOMAO: $0
KALV [@Biotechnology] is valued at $596.59M. XOMAO’s [@Biotechnology] market capitalization is $0. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KALV’s FA Score shows that 0 FA rating(s) are green whileXOMAO’s FA Score has 1 green FA rating(s).

  • KALV’s FA Score: 0 green, 5 red.
  • XOMAO’s FA Score: 1 green, 4 red.
According to our system of comparison, XOMAO is a better buy in the long-term than KALV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KALV’s TA Score shows that 7 TA indicator(s) are bullish.

  • KALV’s TA Score: 7 bullish, 4 bearish.

Price Growth

KALV (@Biotechnology) experienced а +13.85% price change this week, while XOMAO (@Biotechnology) price change was +0.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

KALV is expected to report earnings on Jul 03, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KALV YTD gains are higher at: 41.677 vs. XOMAO (2.969). XOMAO has higher annual earnings (EBITDA): -5.42M vs. KALV (-173.23M). KALV has more cash in the bank: 253M vs. XOMAO (93.3M). KALV has less debt than XOMAO: KALV (5.78M) vs XOMAO (119M). XOMAO has higher revenues than KALV: XOMAO (10.2M) vs KALV (0).
KALVXOMAOKALV / XOMAO
Capitalization597MN/A-
EBITDA-173.23M-5.42M3,194%
Gain YTD41.6772.9691,404%
P/E RatioN/AN/A-
Revenue010.2M-
Total Cash253M93.3M271%
Total Debt5.78M119M5%
FUNDAMENTALS RATINGS
KALV: Fundamental Ratings
KALV
OUTLOOK RATING
1..100
62
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
PROFIT vs RISK RATING
1..100
85
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KALV
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JVACX35.140.22
+0.63%
JPMorgan Value Advantage C
CAPSX8.330.02
+0.24%
Federated Hermes Capital Income IS
WTMVX10.59N/A
N/A
Segall Bryant & Hamill Glb All Cp Retail
LDFVX14.15-0.02
-0.14%
Lord Abbett Fundamental Equity A
BGFRX10.47-0.11
-1.04%
William Blair Growth R6

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
+2.17%
ATXS - KALV
47%
Loosely correlated
+1.51%
IDYA - KALV
44%
Loosely correlated
+5.56%
TRDA - KALV
43%
Loosely correlated
+3.44%
AVIR - KALV
43%
Loosely correlated
-1.00%
RCKT - KALV
42%
Loosely correlated
+2.93%
More

XOMAO and

Correlation & Price change

A.I.dvisor indicates that over the last year, XOMAO has been closely correlated with AMLX. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if XOMAO jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMAO
1D Price
Change %
XOMAO100%
+0.72%
AMLX - XOMAO
68%
Closely correlated
+4.19%
XOMAP - XOMAO
28%
Poorly correlated
-0.57%
ATAI - XOMAO
24%
Poorly correlated
+3.52%
LTRN - XOMAO
23%
Poorly correlated
-2.01%
KALV - XOMAO
23%
Poorly correlated
+2.17%
More